Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2007-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized pilot phase II trial studies the side effects and how well defined green tea catechin extract works in treating patients with localized prostate cancer undergoing surgery. Defined green tea catechin extract contains ingredients that may prevent or slow the growth of certain cancers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate

NCT00459407

Adenocarcinoma of the Prostate Stage I Prostate Cancer Stage II Prostate Cancer

COMPLETED PHASE1

To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

NCT04597359

Prostate Carcinoma

RECRUITING PHASE2

Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery

NCT01912820

Adenocarcinoma of the Prostate Recurrent Prostate Cancer Stage I Prostate Cancer +4 more

COMPLETED PHASE1

Green Tea Extract and Prostate Cancer

NCT00676780

Prostate Cancer

COMPLETED PHASE2

Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer

NCT00666562

Stage I Bladder Cancer Stage II Bladder Cancer Stage III Bladder Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

I. To evaluate the short-term effects of daily Polyphenon E (defined green tea catechin extract) administration (800 mg epigallocatechin-3-gallate \[EGCG\] once daily \[QD\]) during the interval between prostate biopsy and radical prostatectomy (approximately 6 weeks) in men with localized prostate cancer.

II. Compare the change in levels of intermediate biomarkers (Ki-67, B-cell lymphoma 2 \[Bcl2\], cyclin D, KiP1/P27, vascular endothelial growth factor \[VEGF\], and cluster of differentiation \[CD\]31) in biopsy (pre-treatment) and prostatectomy (post-treatment) specimens collected from subjects treated with Polyphenon E or placebo during the period between biopsy and prostatectomy.

III. Compare the change in pre- and post-treatment serum prostate-specific antigen (PSA) level in subjects treated with Polyphenon E or placebo during the period between biopsy and prostatectomy.

IV. Evaluate bioavailability of catechins from Polyphenon E (plasma and tissue catechin levels, catechin metabolites in urine).

V. Evaluate the safety and tolerability of Polyphenon E in this subject population.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive defined green tea catechin extract orally (PO) QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.

ARM II: Patients receive placebo PO QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.

After completion of study treatment, patients are followed up periodically.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stage I Prostate Cancer Stage IIA Prostate Cancer Stage IIB Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Intervention Type OTHER

Correlative studies

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Prostate biopsy positive for cancer; clinically localized T1 and T2 stage disease expected, with biopsy specimen available for baseline biomarker measurements
* Scheduled for a radical prostatectomy
* Willing to sign an Institutional Review Board (IRB)-approved informed consent document and adhere to the protocol
* Willing and able to take oral medications
* Willing to refrain from drinking any kind of tea (including herbal tea) or using supplements containing green tea constituents for the duration of the study

Exclusion Criteria

* Prior hormonal or surgical therapy for prostate cancer; including prior brachytherapy or radiation therapy
* Recent consumption of tea (six or more cups per day) or use of supplements containing green tea within one week of randomization
* Signs or symptoms of progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic or cerebral disease
* Serum creatinine \>= 1.5 x upper limit of normal (ULN)
* Alanine aminotransferase (ALT) \>= ULN
* Aspartate aminotransferase (AST) \>= ULN
* Alkaline phosphatase (ALP) \>= ULN
* Albumin (ALB) =\< lower limit of normal (LLN)
* Total bilirubin \>= ULN
* Known malignancy at any site within the last five years; with the exception of basal cell carcinoma (BCC)
* Participation in a research trial within the past three months
* Any condition that would interfere with the ability to give informed consent or comply with the study protocol
* Hypersensitivity to tea products or any of the inactive ingredients found in the drug product capsules
* Concomitant use of at least 400 mg per day of a nonsteroidal anti-inflammatory (NSAID) agent two or more times per week

Minimum Eligible Age

45 Years

Maximum Eligible Age

75 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No